Controlled attenuation parameter (CAP) for detection of hepatic steatosis in patients with chronic liver diseases: A prospective study of a native Korean population

Young Eun Chon, Kyu Sik Jung, Seung Up Kim, Jun Yong Park, Young Nyun Park, Do Young Kim, Sang Hoon Ahn, Chae Yoon Chon, Hye Won Lee, Yehyun Park, Kwang Hyub Han

Research output: Contribution to journalArticle

77 Citations (Scopus)

Abstract

Background: Controlled attenuation parameter (CAP) is a non-invasive method of measuring hepatic steatosis using a process based on transient elastography. We investigated the diagnostic accuracy of CAP in detecting hepatic steatosis in patients with chronic liver disease (CLD). Methods: A total of 135 patients with CLD who underwent liver biopsy and CAP were consecutively enrolled in this prospective study. The performance of CAP for detection of hepatic steatosis compared with liver biopsy was calculated using area under receiver operating characteristics curves (AUROC). Steatosis was categorized into S0 (<5%), S1 (5-33%), S2 (34-66%) and S3 (>66% of hepatocytes). Results: Male gender predominated (n = 87, 64%) and the median age was 51 years. The aetiologies of CLD included non-alcoholic fatty liver disease (n = 56, 41.5%) and chronic viral hepatitis because of hepatitis B (n = 47, 34.8%) and C (n = 12, 8.9%). Steatosis repartition was: S0 31.1% (n = 42), S1 43.7% (n = 59), S2 18.5% (n = 25) and S3 6.7% (n = 9) respectively. In the multivariate analysis, steatosis grade and body mass index were independently associated with CAP (all P < 0.001), whereas fibrosis stage and activity grade were not. The AUROCs of CAP were 0.885 for ≥S1 (sensitivity 73.1%, specificity 95.2%), 0.894 for ≥S2 (sensitivity 82.4%, specificity 86.1%) and 0.800 for S3 (sensitivity 77.8%, specificity 84.1%). The optimal cut-off CAP values that maximized the Youden index were 250 dB/m (≥S1), 299 dB/m (≥S2), and 327 dB/m (=S3) respectively. Conclusions: Our data showed that CAP had high diagnostic accuracy for detecting hepatic steatosis in patients with CLD and suggested that CAP is also applicable for Asian patients.

Original languageEnglish
Pages (from-to)102-109
Number of pages8
JournalLiver International
Volume34
Issue number1
DOIs
Publication statusPublished - 2014 Jan 1

Fingerprint

Liver Diseases
Chronic Disease
Prospective Studies
Liver
Population
Sensitivity and Specificity
Biopsy
Elasticity Imaging Techniques
Chronic Hepatitis
Hepatitis B
ROC Curve
Hepatocytes
Body Mass Index
Fibrosis
Multivariate Analysis

All Science Journal Classification (ASJC) codes

  • Hepatology

Cite this

@article{ad92daa163904cebb343a4c469b68a96,
title = "Controlled attenuation parameter (CAP) for detection of hepatic steatosis in patients with chronic liver diseases: A prospective study of a native Korean population",
abstract = "Background: Controlled attenuation parameter (CAP) is a non-invasive method of measuring hepatic steatosis using a process based on transient elastography. We investigated the diagnostic accuracy of CAP in detecting hepatic steatosis in patients with chronic liver disease (CLD). Methods: A total of 135 patients with CLD who underwent liver biopsy and CAP were consecutively enrolled in this prospective study. The performance of CAP for detection of hepatic steatosis compared with liver biopsy was calculated using area under receiver operating characteristics curves (AUROC). Steatosis was categorized into S0 (<5{\%}), S1 (5-33{\%}), S2 (34-66{\%}) and S3 (>66{\%} of hepatocytes). Results: Male gender predominated (n = 87, 64{\%}) and the median age was 51 years. The aetiologies of CLD included non-alcoholic fatty liver disease (n = 56, 41.5{\%}) and chronic viral hepatitis because of hepatitis B (n = 47, 34.8{\%}) and C (n = 12, 8.9{\%}). Steatosis repartition was: S0 31.1{\%} (n = 42), S1 43.7{\%} (n = 59), S2 18.5{\%} (n = 25) and S3 6.7{\%} (n = 9) respectively. In the multivariate analysis, steatosis grade and body mass index were independently associated with CAP (all P < 0.001), whereas fibrosis stage and activity grade were not. The AUROCs of CAP were 0.885 for ≥S1 (sensitivity 73.1{\%}, specificity 95.2{\%}), 0.894 for ≥S2 (sensitivity 82.4{\%}, specificity 86.1{\%}) and 0.800 for S3 (sensitivity 77.8{\%}, specificity 84.1{\%}). The optimal cut-off CAP values that maximized the Youden index were 250 dB/m (≥S1), 299 dB/m (≥S2), and 327 dB/m (=S3) respectively. Conclusions: Our data showed that CAP had high diagnostic accuracy for detecting hepatic steatosis in patients with CLD and suggested that CAP is also applicable for Asian patients.",
author = "Chon, {Young Eun} and Jung, {Kyu Sik} and Kim, {Seung Up} and Park, {Jun Yong} and Park, {Young Nyun} and Kim, {Do Young} and Ahn, {Sang Hoon} and Chon, {Chae Yoon} and Lee, {Hye Won} and Yehyun Park and Han, {Kwang Hyub}",
year = "2014",
month = "1",
day = "1",
doi = "10.1111/liv.12282",
language = "English",
volume = "34",
pages = "102--109",
journal = "Liver International",
issn = "1478-3223",
publisher = "Wiley-Blackwell",
number = "1",

}

Controlled attenuation parameter (CAP) for detection of hepatic steatosis in patients with chronic liver diseases : A prospective study of a native Korean population. / Chon, Young Eun; Jung, Kyu Sik; Kim, Seung Up; Park, Jun Yong; Park, Young Nyun; Kim, Do Young; Ahn, Sang Hoon; Chon, Chae Yoon; Lee, Hye Won; Park, Yehyun; Han, Kwang Hyub.

In: Liver International, Vol. 34, No. 1, 01.01.2014, p. 102-109.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Controlled attenuation parameter (CAP) for detection of hepatic steatosis in patients with chronic liver diseases

T2 - A prospective study of a native Korean population

AU - Chon, Young Eun

AU - Jung, Kyu Sik

AU - Kim, Seung Up

AU - Park, Jun Yong

AU - Park, Young Nyun

AU - Kim, Do Young

AU - Ahn, Sang Hoon

AU - Chon, Chae Yoon

AU - Lee, Hye Won

AU - Park, Yehyun

AU - Han, Kwang Hyub

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Background: Controlled attenuation parameter (CAP) is a non-invasive method of measuring hepatic steatosis using a process based on transient elastography. We investigated the diagnostic accuracy of CAP in detecting hepatic steatosis in patients with chronic liver disease (CLD). Methods: A total of 135 patients with CLD who underwent liver biopsy and CAP were consecutively enrolled in this prospective study. The performance of CAP for detection of hepatic steatosis compared with liver biopsy was calculated using area under receiver operating characteristics curves (AUROC). Steatosis was categorized into S0 (<5%), S1 (5-33%), S2 (34-66%) and S3 (>66% of hepatocytes). Results: Male gender predominated (n = 87, 64%) and the median age was 51 years. The aetiologies of CLD included non-alcoholic fatty liver disease (n = 56, 41.5%) and chronic viral hepatitis because of hepatitis B (n = 47, 34.8%) and C (n = 12, 8.9%). Steatosis repartition was: S0 31.1% (n = 42), S1 43.7% (n = 59), S2 18.5% (n = 25) and S3 6.7% (n = 9) respectively. In the multivariate analysis, steatosis grade and body mass index were independently associated with CAP (all P < 0.001), whereas fibrosis stage and activity grade were not. The AUROCs of CAP were 0.885 for ≥S1 (sensitivity 73.1%, specificity 95.2%), 0.894 for ≥S2 (sensitivity 82.4%, specificity 86.1%) and 0.800 for S3 (sensitivity 77.8%, specificity 84.1%). The optimal cut-off CAP values that maximized the Youden index were 250 dB/m (≥S1), 299 dB/m (≥S2), and 327 dB/m (=S3) respectively. Conclusions: Our data showed that CAP had high diagnostic accuracy for detecting hepatic steatosis in patients with CLD and suggested that CAP is also applicable for Asian patients.

AB - Background: Controlled attenuation parameter (CAP) is a non-invasive method of measuring hepatic steatosis using a process based on transient elastography. We investigated the diagnostic accuracy of CAP in detecting hepatic steatosis in patients with chronic liver disease (CLD). Methods: A total of 135 patients with CLD who underwent liver biopsy and CAP were consecutively enrolled in this prospective study. The performance of CAP for detection of hepatic steatosis compared with liver biopsy was calculated using area under receiver operating characteristics curves (AUROC). Steatosis was categorized into S0 (<5%), S1 (5-33%), S2 (34-66%) and S3 (>66% of hepatocytes). Results: Male gender predominated (n = 87, 64%) and the median age was 51 years. The aetiologies of CLD included non-alcoholic fatty liver disease (n = 56, 41.5%) and chronic viral hepatitis because of hepatitis B (n = 47, 34.8%) and C (n = 12, 8.9%). Steatosis repartition was: S0 31.1% (n = 42), S1 43.7% (n = 59), S2 18.5% (n = 25) and S3 6.7% (n = 9) respectively. In the multivariate analysis, steatosis grade and body mass index were independently associated with CAP (all P < 0.001), whereas fibrosis stage and activity grade were not. The AUROCs of CAP were 0.885 for ≥S1 (sensitivity 73.1%, specificity 95.2%), 0.894 for ≥S2 (sensitivity 82.4%, specificity 86.1%) and 0.800 for S3 (sensitivity 77.8%, specificity 84.1%). The optimal cut-off CAP values that maximized the Youden index were 250 dB/m (≥S1), 299 dB/m (≥S2), and 327 dB/m (=S3) respectively. Conclusions: Our data showed that CAP had high diagnostic accuracy for detecting hepatic steatosis in patients with CLD and suggested that CAP is also applicable for Asian patients.

UR - http://www.scopus.com/inward/record.url?scp=84890119533&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890119533&partnerID=8YFLogxK

U2 - 10.1111/liv.12282

DO - 10.1111/liv.12282

M3 - Article

C2 - 24028214

AN - SCOPUS:84890119533

VL - 34

SP - 102

EP - 109

JO - Liver International

JF - Liver International

SN - 1478-3223

IS - 1

ER -